Small Molecule · MT1980

MT1980

MT1980 is an oral, lipid-based reformulation of an already-marketed fibrate-class lipid-modifying drug (a PPAR-alpha agonist), developed by Monument Therapeutics (Manchester, UK) using TRx Biosciences' LipiCore oral delivery technology, which is exclusively licensed to Monument for MT1980. The reformulation is designed to overcome the poor blood-brain barrier penetration of standard formulations so the drug's anti-inflammatory pharmacology can act in the brain. A single-dose Phase 1 study in healthy volunteers (NCT05429840, 2022) found it well tolerated and detected drug in the cerebrospinal fluid of every volunteer. Monument first positioned it for neuroinflammation-associated conditions such as post-operative cognitive decline, Alzheimer's disease and Long COVID; at ECNP 2026 it presented MT1980 for inflammation-associated schizophrenia, with a multiple-ascending-dose study and a proof-of-principle trial in schizophrenia patients with elevated inflammation and negative symptoms planned. The specific active ingredient has not been publicly named.

Also known as: MT1980, MT-1980

Key facts

Modality
Small molecule
Chemical class
fibrate
Mechanism
PPAR-alpha agonist
Highest phase
Phase 1
Lead indication
Schizophrenia
Trials
1 tracked

Mechanism of action#

MT1980 delivers a marketed fibrate-class lipid-modifying drug in a lipid formulation designed to raise systemic exposure and reach the brain. According to Monument's ECNP 2026 poster it acts as a PPAR-alpha agonist with additional anti-inflammatory actions. In preclinical studies, MT1980 and the standard formulation both lowered peripheral inflammatory markers, but only MT1980 significantly reduced inflammatory cytokines in brain tissue in a lipopolysaccharide (LPS) neuroinflammation model. The hypothesis is that central PPAR-alpha-mediated dampening of neuroinflammation, and the downstream effects on the kynurenine pathway, may improve negative symptoms in the subgroup of schizophrenia patients with raised inflammatory markers, while the drug's lipid-lowering effects address cardiometabolic burden.

TargetActionAffinity
PPAR-alphaprimaryPPARAAgonist—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
MT1980 oral lipid (LipiCore) formulationLipiCore lipid-based oral delivery (TRx Biosciences)
Single oral doses of 70 mg, 140 mg or 250 mg versus placebo, given fasted, in the first-in-human Phase 1 study (NCT05429840). No repeat-dose regimen has been tested; a multiple-dose Phase 1 is planned.
OralSingle dose—

Development timeline#

20222023202420252026TodayPhase 110 Oct 2026 — Conference presentation — MT1980 presented for inflammation-associated schizophrenia at ECNP 2026 (poster PS01-1249)17 Sept 2024 — Patent granted — UK patent GB2616923 granted in support of MT19809 Jan 2023 — readout (met) — First-in-human single-dose Phase 1 of MT1980 met all objectives: drug was found in the cerebrospinal fluid of every healthy volunteer, and there were no significant MT1980-related side effects.4 Oct 2022 — phase change — NCT05429840 completed (actual primary completion 2022-10-04, 24 participants). Monument reported on 2023-01-09 that the study met all objectives. A multiple-dose Phase 1 has been planned since then but is not registered.4 Oct 2022 — Trial (portion) completed — MT1980 first-in-human Phase 1 completes (NCT05429840)1 Jun 2022 — phase change — First-in-human single-dose Phase 1 NCT05429840 (protocol PCD101) started per ClinicalTrials.gov. It enrolled healthy volunteers and was registered under 'Neuroinflammatory Response', not schizophrenia. Monument announced the start on 2022-06-13.1 Jun 2022 — Trial started — First-in-human Phase 1 of MT1980 starts (NCT05429840)14 Mar 2022 — Preclinical Data — Monument to present positive preclinical PK/PD data for MT1980 at AD/PD 202214 Dec 2021 — Financing — Monument Therapeutics raises an additional GBP 0.5 million to take MT1980 into the clinic
Phase change Readout Event UpcomingHover a marker for details.
Phase 1Dec 2021 – Oct 2026
  1. Conference presentationMT1980 presented for inflammation-associated schizophrenia at ECNP 2026 (poster PS01-1249)↗
  2. Patent grantedUK patent GB2616923 granted in support of MT1980↗
  3. metFirst-in-human single-dose Phase 1 of MT1980 met all objectives: drug was found in the cerebrospinal fluid of every healthy volunteer, and there were no significant MT1980-related side effects.↗
  4. NCT05429840 completed (actual primary completion 2022-10-04, 24 participants). Monument reported on 2023-01-09 that the study met all objectives. A multiple-dose Phase 1 has been planned since then but is not registered.
  5. Trial (portion) completedMT1980 first-in-human Phase 1 completes (NCT05429840)
  6. First-in-human single-dose Phase 1 NCT05429840 (protocol PCD101) started per ClinicalTrials.gov. It enrolled healthy volunteers and was registered under 'Neuroinflammatory Response', not schizophrenia. Monument announced the start on 2022-06-13.
  7. Trial startedFirst-in-human Phase 1 of MT1980 starts (NCT05429840)
  8. Preclinical DataMonument to present positive preclinical PK/PD data for MT1980 at AD/PD 2022↗
  9. FinancingMonument Therapeutics raises an additional GBP 0.5 million to take MT1980 into the clinic↗

MT1980 for Schizophrenia#

Phase 1ActiveSchizophrenia indication →

MT1980, Monument Therapeutics' brain-penetrant lipid reformulation of a marketed fibrate (a PPAR-alpha agonist), for schizophrenia in patients with elevated inflammation and persistent negative symptoms. Human data so far come from one completed single-dose Phase 1 in 24 healthy volunteers (NCT05429840, 2022; Groningen, Netherlands). It was well tolerated and drug reached the cerebrospinal fluid at every dose level (70, 140, 250 mg). At ECNP 2026 Monument presented the schizophrenia rationale and described next steps: a multiple-ascending-dose study in healthy volunteers, then a proof-of-principle study in schizophrenia patients selected for raised inflammatory markers and negative symptoms, with inflammatory and pharmacodynamic biomarkers. Neither study is registered. The multiple-dose Phase 1 has been described as planned since January 2023. The compound's indication focus has shifted over time, from post-operative cognitive decline (2021) to Alzheimer's disease, POCD and Long COVID (2023-2024) to inflammation-associated schizophrenia (2026).

Readouts

  • 2023-01-09ReportedTopline datametNCT05429840

    First-in-human single-dose Phase 1 of MT1980 met all objectives: drug was found in the cerebrospinal fluid of every healthy volunteer, and there were no significant MT1980-related side effects. ↗

Clinical trials#

NCT05429840PCD101Phase 1Completedn=24

A Two-part, Single Dose, Randomized, Single Blinded, Placebo Controlled, Phase I Study to Assess the Safety and Pharmacokinetics of Oral MT1980 in Healthy Volunteers When Dosed in the Fasted State

Started Jun 2022· Primary completion Oct 2022

Conference coverage#

MT1980 appears in 1 CNS Pulse conference abstract:

Sources#

  1. Granger KT, Moran P, Caswell S, Barnett J. MT1980: translating anti-inflammatory and metabolic mechanisms into new treatment opportunities for schizophrenia. ECNP 2026, poster PS01-1249 — CNS Pulse (ECNP 2026 abstract)
  2. Monument Therapeutics announces first clinical study of MT1980 has successfully met all objectives (2023-01-09) — Monument Therapeutics
  3. Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980 (2024-09-17) — Monument Therapeutics
  4. Monument Therapeutics to present positive data for first clinical study of MT1980 at AD/PD conference (2023-03-28) — Monument Therapeutics
  5. Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference (2022-03-14) — Monument Therapeutics (via One Nucleus)
  6. NCT05429840 (PCD101) - Safety & PK of Single Doses of MT1980 — ClinicalTrials.gov (U.S. National Library of Medicine)
  7. Stratified medicine company Monument Therapeutics raises additional GBP 0.5 million to take anti-neuroinflammation candidate MT1980 into clinic (2021-12-14) — Monument Therapeutics